2026 ASH Annual Meeting Press Program

Moderator: Carla Casulo, MD, University of Rochester Medicine

Time: Wednesday, Dec. 9 at 11:00 a.m. ET

Abstract 0006: Superior progression-free survival with zanubrutinib plus rituximab vs bendamustine-rituximab in treatment-naïve mantle cell lymphoma (TN MCL): Primary analysis of a phase 3 study (MANGROVE)
Abstract 0919: Epcoritamab plus lenalidomide (E-Len) compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx): Primary results from the phase 3 EPCORE DLBCL-4 study in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Abstract 0920: Results from the Phase 3 LOTIS-5 study: Efficacy and safety of loncastuximab tesirine plus rituximab vs immunochemotherapy (R-GemOx) in patients with relapsed or refractory DLBCL
Abstract 0540: Acalabrutinib plus venetoclax vs venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia: Interim results from the randomized, global, phase 3 MAJIC study

Moderator: Surbhi Sidana, MD, Stanford University

Time: Saturday, December 12 at 7:30 a.m. CT

Abstract 0114: Progression-free survival (PFS) and minimal residual disease (MRD) outcomes with iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 excaliber-RRMM study
Abstract 0426: Primary Analysis of the phase 3 randomized MonumenTAL-6 study of teclistamab (Tec) plus talquetamab (Tal) or Tal plus pomalidomide (Pom) vs investigator's choice of elotuzumab, Pom and dexamethasone (EPd) or Pom, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and 1–4 prior lines of therapy (LOT)
Abstract 0424: Elranatamab (ELRA) monotherapy versus daratumumab plus pomalidomide and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM): Results from the phase 3 MagnetisMM-5 trial
Abstract 0110: Ramantamig, daratumumab (Dara), and lenalidomide (R) in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM) in the phase 2 MajesTEC-5 trial: First results of a trispecific antibody in NDMM

Moderator: Rakhi Naik, MD, Johns Hopkins University

Time: Saturday, Dec. 12 at 9:00 a.m. CT

Abstract 0726: Prevalence and clinical significance of iron deficiency without anemia in a prospective cohort of pregnant women receiving community obstetric care
Abstract 0331: Oral epeleuton reduces vaso-occlusive crisis burden in adults with sickle cell disease: Results from a Phase 2 study
Abstract 0335: Efficacy, safety, and patient-reported outcomes of risto-cel in adolescents and adults with sickle cell disease: Interim results from the BEACON study
Abstract 0003: Chronic red cell exchange transfusions to prevent clinical worsening in high-risk adults with sickle cell disease: Results from the SCD-CARRE trial
Abstract 0601: Hemophilia A genotype status predicts bleeding in females, while FVIII levels fail to identify a “safe” female FVIII threshold in my life, our future.

Moderator: Mikkael Sekeres, MD, MS, Sylvester Comprehensive Cancer Center at the University of Miami

Time: Sunday, Dec. 13 at 7:00 a.m. CT

Abstract 0569: Fecal microbiota transplantation to prevent graft-versus-host disease: Results from a phase II randomized double-blind placebo-controlled trial
Abstract 0001: Superior event-free survival with ivosidenib plus intensive chemotherapy in newly diagnosed IDH1-mutated AML: Results from the phase 3 HOVON150/AMLSG29-18 trial
Abstract 0559: CD22 CAR T cells co-administered with humanized CD19 CAR T cells induce durable remissions in highly refractory pediatric and young adult B-ALL with prior CD19 CAR failure: Results of a phase 1/2 trial
Abstract 0901: Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Phase 2 results from the VICEROY study

Briefing: TBD